Glenmark

Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19. The company has received manufacturing and marketing approval…

View Post

Latest News
Spotlight

Glenmark To Commence Another New Phase 3 Clinical Trial On A Combination Of Two Anti-Viral Drugs Favipiravir And Umifenovir

May 26, 2020 14:06
Healthwire Bureau

Glenmark Pharmaceuticals Ltd Glenmark has announced to commence another new phase 3 Clinical Trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in Hospitalized Patients of Moderate COVID-19…

View Post

Menu

Glenmark

Glenmark Launches COVID-19 Drug FabiFlu After DCGI Nod

Glenmark To Commence Another New Phase 3 Clinical Trial On A Combination Of Two Anti-Viral Drugs Favipiravir And Umifenovir

World Antimicrobial resistance (AMR) Awareness Week 2024

Cervical cancer elimination day of action

IIT Madras Study Reveals Oral Contraceptives Don’t Raise Blood Pressure in Female Athletes

Zilebesiran: Single Dose Shows Six-Month Blood Pressure Control in Hypertension Breakthrough

Fasting Enhances Glucose Regulation for Night Shift Employees: Study Finds

Parkinson’s Disease To Surge To 3.15 Million Worldwide By 2033: Warns Report

Experts Warn: Air Pollution Can Trigger Heart Attacks, Here’s How PM2.5 Can Cause Damage Arteries

Burning Eyes, Difficulty In Breathing: Toxic Delhi Smog And 500 AQI Levels Leave Residents Helpless